Introduction {#s2}
============

Selective clinical trial publication, including nonpublication and delayed publication of completed trials, distorts the evidence available in the medical literature, compromising systematic reviews and meta-analyses, impairing evidence-based clinical practice, and undermining guideline recommendations. The extent of selective publication is not known, but previous studies have estimated between 25%--50% of supporting trials for US Food and Drug Administration (FDA)-approved drugs remained unpublished more than 5 y after approval [@pmed.1000144-Lee1],[@pmed.1000144-Rising1]. Similarly unpublished clinical trials of rosiglitazone [@pmed.1000144-Nissen1] identified from a company-maintained website and of erythropoiesis-stimulating agents [@pmed.1000144-Bennett1] and antidepressants [@pmed.1000144-Turner1] found among data submitted to the FDA revealed important efficacy and safety information to be missing from the medical literature. Such selective publication is raising questions about the frequency with which trials are unpublished and how best to ensure timely public and professional access to all trial results.

Section 113 of the 1997 FDA Modernization Act was enacted in the United States over 10 y ago to provide the public access to information about ongoing clinical trials in which they may be able to participate. The act required the creation of a public resource for information on studies of drugs, including biological drug products, which treat "serious or life-threatening" diseases and conditions conducted under the FDA\'s investigational new drug regulations, mandating the collection of specific descriptive information pertaining to each clinical trial. In response, the US National Library of Medicine (NLM) established the Web-based registry ClinicalTrials.gov in 2000, on behalf of the US National Institutes of Health (NIH), providing what was intended to be a publicly available, easily searchable, on-line source of information for all registered trials, including trials located domestically within the US and internationally. This registry has the potential to address selective publication by publicly cataloguing clinical trials and promoting trial transparency and accountability. In 2004, the International Committee of Medical Journal Editors (ICMJE) announced that any clinical trial must be registered by September 2005 in a public clinical trials registry that satisfied several specifications to be considered for publication in one of its journals; at that time, only ClinicalTrials.gov met the specifications put forth by the editors [@pmed.1000144-DeAngelis1]. Between May and October 2005, the number of trials registered within ClinicalTrials.gov increased by 73% [@pmed.1000144-Zarin1].

Despite these efforts, problems with the Web-based registry have been identified. An audit in 2005 of ClinicalTrials.gov by investigators at the NLM found one-quarter of registered trials did not describe the primary outcome defined within the study, and many of those that did lacked specific information about its timing and measurement [@pmed.1000144-Zarin1]. No published study, however, has systematically examined the frequency and timeliness with which results of trials registered within ClinicalTrials.gov are published in the medical literature, a measure of how well ClinicalTrials.gov might be addressing selective publication.

The FDA Amendments Act (FDAAA), enacted in September 2007 in the US, included new initiatives to use ClinicalTrials.gov to further address selective publication. The legislation requires the sponsors of all drug, biologic, and device trials to register their studies, at inception, in the publicly available ClinicalTrials.gov database (with the exception of phase I clinical trials). Moreover, the registry must be updated to include information on participants and trial results for approved drugs and devices within 12 mo of study completion (24 mo if the studied drug is currently under review at the FDA); specifically, investigators must report the primary and principal secondary outcome results to ClinicalTrials.gov for publication within the registry. As details of legislation implementation remain under negotiation, there is a need for information about currently registered studies and the extent of selective publication. While this information is clearly relevant to policy-makers, it also has profound implications in terms of the evidence made available for clinicians, researchers, and patients. Accordingly, our objectives were to determine the completeness of registrations within ClinicalTrials.gov and determine the extent and correlates of selective publication.

Methods {#s3}
=======

Overview {#s2a}
--------

ClinicalTrials.gov uses a Web-based system to facilitate clinical trial registration by any sponsor, principal investigator, or other person or organization with primary responsibility for the trial. Trials are defined by ClinicalTrials.gov as "... Research studies in human volunteers to answer specific health questions. Interventional trials determine whether experimental treatments or new ways of using known therapies are safe and effective under controlled environments. Observational trials address health issues in large groups of people or populations in natural settings" [@pmed.1000144-U.S.NationalInstitutesofHealth1]. ClinicalTrials.gov serves as a registry for trials located both in the US and internationally and multisite clinical trials that are conducted using the same protocol are considered one trial in the registry. ClinicalTrials.gov includes mandatory and optional data elements ([Table S1](#pmed.1000144.s001){ref-type="supplementary-material"}). Trials cannot be registered without completion of all mandatory data elements, approval by a human subject review board (or equivalent), and conformity to the regulations of the appropriate national health authorities. Additional information about the registry is available from the NLM [@pmed.1000144-U.S.NationalInstitutesofHealth2].

Study Sample and Variables for Completeness Analysis {#s2b}
----------------------------------------------------

Among more than 42,000 trials registered within ClinicalTrials.gov as of June 2007, we limited our study to clinical trials that were registered after December 31, 1999 and whose registry was updated to notify ClinicalTrials.gov that the trial had been completed as of June 8, 2007, excluding phase I trials ([Figure 1](#pmed-1000144-g001){ref-type="fig"}). A completed trial is defined by ClinicalTrials.gov as a study that has concluded and participants are no longer being examined or treated (i.e., last patient\'s last visit has occurred) [@pmed.1000144-U.S.NationalInstitutesofHealth3]. We obtained information on these trials through a request to the NLM, requesting the following mandatory data elements for each trial: identification number, title, primary sponsor, study official, design, type, phase (if interventional), intervention, condition, and population studied, along with the following optional data elements: enrollment, trial start and end dates, primary and secondary outcome measures, and publication. These data elements were requested (as opposed to all data elements) because we determined that each was relevant for identifying publications of registered trials and for examining associations between publication and several trial characteristics (e.g., sponsorship, condition studied). Data from the NLM were provided in a spreadsheet. Categorizations of data elements are made by study investigators/sponsors as part of trial registration. For instance, primary condition studied was assigned to one of 23 categories, primary study sponsor to one of six. We further categorized sponsor into three groups: government (US or non-US), industry, or nongovernment/nonindustry, which included universities, organizations, foundations, and clinical research networks. We used study design to categorize study purpose as efficacy only, efficacy and safety, safety only, or indeterminate. For instance, a study design of "Treatment/Randomized/Placebo Control/Safety/Efficacy Study" was categorized as efficacy and safety, whereas a study design of "Treatment/Randomized/Placebo Control/Safety Study" was categorized as safety only.

![ClinicalTrials.gov trial inclusion flow chart.](pmed.1000144.g001){#pmed-1000144-g001}

Study Sample and Variables for Publication Analysis {#s2c}
---------------------------------------------------

From our full sample of completed trials, we created a 10% subsample by assigning each trial a random number and selecting those first in the randomization sequence to determine their publication status. For this analysis, we also excluded trials with a registered end date after December 31, 2005, in order to provide at least a 2 y period within which trials might be published, consistent with FDAAA legislation. For those trials that did not provide an end date within ClinicalTrials.gov, but did provide a start date, we excluded trials for which data collection started after June 30, 2005 for the same reason. We also excluded trials that studied complementary and alternative medicine, such as acupuncture or ginseng, as they were not our focus and we were concerned that these trials were not appropriate for comparison with "traditional" biomedical trials.

For all trials within the 10% subsample, we determined the following: publication status, study type, randomized design, and study location. Two of three authors (JSR, GKM, EMH) independently determined the publication status using a search protocol. All searches began by first examining the "publication" field within ClinicalTrials.gov to determine if trial investigators provided a citation of an article that described trial results, as this field is used to display citations of trial results or other relevant research, as provided by investigators. If no citation was provided, we then searched MEDLINE using the ClinicalTrials.gov identification number. If no publication was identified, MEDLINE was again searched using the intervention, condition studied, and the principal investigator (when provided in response to the "study official" field). The articles identified through the search were matched to the corresponding trial (when possible) using the following information from ClinicalTrials.gov: description, location, enrollment, start and end dates, and primary and secondary outcome measures. Any differences were resolved by consensus. Finally, if no publication was identified, we attempted to contact the study official identified within ClinicalTrials.gov to determine if the trial had been published, limiting our attempts to a maximum of three electronic mail messages.

Once a publication was identified for a registered trial, we determined whether the primary outcome described in the manuscript was the same as the primary outcome described within ClinicalTrials.gov.

Statistical Analysis {#s2d}
--------------------

We conducted a descriptive analysis, describing data quality, including completeness of reporting for each data element, and summarizing the characteristics of our sample by primary sponsor, type, purpose, phase, location, and condition and population studied. We then used Chi-square tests to examine the association between these trial characteristics and publication status. Because our 10% subsample excluded trials with a registered end date after December 31, 2005 in order to provide at least 2 y for publication, but included trials that did not report an end date, we examined the robustness of our results in two ways. First, we tested the interaction between end date reporting (yes/no) and each trial characteristic whose association with publication status was examined (i.e., sponsor, study location). No trial characteristic variable interacted significantly with end date reporting. Second, we repeated our analyses using a time-to-publication approach among only those trials that reported a trial end date. These analyses confirmed our main findings. Therefore, only the results from the full 10% subsample analyses are presented. Statistical analysis was performed using JMP 7.0.1 and SAS 9.1 (both from SAS Institute, Inc.). All statistical tests were two-tailed, using a type I error rate of 0.005 to account for multiple comparisons. Yale University Human Investigation Committee approval was obtained prior to the study.

Results {#s4}
=======

Completeness Analyses {#s3a}
---------------------

There were 7,515 registered clinical trials in our analysis. Nearly 100% of records provided all mandatory data elements: title, sponsor, condition studied, design, type, phase, and intervention and population studied. Study official, which is also a mandatory data element, was also provided by 100% of records, with varying degrees of specificity: 63% provided the principal investigator contact name, whereas the others provided another study contact, such as the name of an institution, company, or facility. Reporting of optional data elements varied; 82% provided enrollment, 87% start date, 53% end date, 66% primary outcome measure, and 56% secondary outcome measure(s).

Nearly half of trials (44%) were primarily sponsored by industry, and cancer was the most common condition studied (13%, [Table 1](#pmed-1000144-t001){ref-type="table"}). Few studies described trials that were conducted only for safety (4%), although most were described as being conducted for safety and efficacy (44%). Among interventional trials, 34% were described as phase III or phase II/III, 31% were phase II or phase I/II, and 18% were phase IV. More than one-quarter of trials enrolled children (28%).

10.1371/journal.pmed.1000144.t001

###### Characteristics of completed trials registered in the ClinicalTrials.gov database after December 31, 1999 (excluding phase I trials).

![](pmed.1000144.t001){#pmed-1000144-t001-1}

  Trial Characteristic                                *n* (%)[a](#nt101){ref-type="table-fn"} (*n* = 7,515)        
  --------------------------------------------- ------------------------------------------------------------------ -------------
  Sponsor                                                                    Industry                               3,330 (44%)
                                                                    Nongovernment/Nonindustry                       2,824 (38%)
                                                                    Government (US and non-US)                      1,361 (18%)
  Condition studied                                                Cancers and other neoplasms                       973 (13)
                                                                  Behaviors and mental disorders                     727 (10)
                                                                     Heart and blood diseases                        727 (10)
                                                                Nutritional and metabolic diseases                    687 (9)
                                                 Conditions of the urinary tract and sexual organs, and pregnancy     522 (7)
                                                                          Viral diseases                              467 (6)
                                                                     Nervous system diseases                          461 (6)
                                                         Respiratory tract (lung and bronchial) diseases              363 (5)
                                                                  Bacterial and fungal diseases                       260 (4)
                                                                              Other                                 2,328 (31)
  Study purpose                                                        Safety and efficacy                          3,304 (44)
                                                                          Efficacy only                             1,737 (23)
                                                                           Safety only                                297 (4)
                                                                          Indeterminate                             2,177 (29)
  Study type                                                              Interventional                            6,674 (89)
                                                                          Observational                              841 (11)
  Study phase[b](#nt102){ref-type="table-fn"}                      Phase I/phase II or phase II                     2,059 (31)
                                                                 Phase II/phase III or phase III                    2,295 (34)
                                                                             Phase IV                               1,110 (17)
                                                                          Not applicable                            1,209 (18)
  Population studied                                                     Included adults                            6,850 (91)
                                                                Included older adults (age ≥65 y)                   5,468 (73)
                                                                        Included children                           2,076 (28)

Proportions may not sum to 100 because of rounding.

Data element is only required to be reported for interventional studies (*n* = 6,674).

Publication Analyses {#s3b}
--------------------

The random 10% subsample included 752 trials and 75 met at least one of our additional exclusion criteria ([Figure 1](#pmed-1000144-g001){ref-type="fig"}). Among 677 included trials, 311 (46%) were published and indexed within MEDLINE ([Table 2](#pmed-1000144-t002){ref-type="table"}). Of these, 215 (69%) did not provide a citation within ClinicalTrials.gov of an article that described trial results, whereas 96 (31%) did.

10.1371/journal.pmed.1000144.t002

###### Publication rates stratified by trial characteristics among a 10% random subsample of completed trials registered in the ClinicalTrials.gov database.

![](pmed.1000144.t002){#pmed-1000144-t002-2}

  Trial Characteristic                                                *n* of Trials Published/Total *n* (%)                   *p*-Value
  ------------------------------------------------------------------ --------------------------------------- --------------------------------------------
  Overall                                                                         311/677 (46)                                   ---
  Sponsor                                                                              ---                      0.003[\*](#nt103){ref-type="table-fn"}
  Industry                                                                        144/357 (40)                                   ---
  Nongovernment/nonindustry                                                       110/198 (56)                                   ---
  Government agencies (US and non-US)                                              57/122 (47)                                   ---
   NIH (US)                                                                        30/74 (41)                                    ---
   US federal agency, excluding NIH                                                19/34 (56)                                    ---
   Government, excluding US federal                                                 8/14 (57)                                    ---
  Condition studied                                                                    ---                                       0.23
  Cancers and other neoplasms                                                      43/102 (42)                                   ---
  Behaviors and mental disorders                                                   33/62 (53)                                    ---
  Heart and blood diseases                                                         22/46 (48)                                    ---
  Nutritional and metabolic diseases                                               24/52 (46)                                    ---
  Conditions of the urinary tract and sexual organs, and pregnancy                 24/43 (56)                                    ---
  Viral diseases                                                                   18/54 (33)                                    ---
  Nervous system diseases                                                          21/44 (48)                                    ---
  Respiratory tract (lung and bronchial) diseases                                  13/40 (33)                                    ---
  Bacterial and fungal diseases                                                    22/40 (55)                                    ---
  Other                                                                            91/194 (47)                                   ---
  Study purpose                                                                        ---                                       0.23
  Safety and efficacy                                                             139/307 (45)                                   ---
  Efficacy only                                                                    71/133 (53)                                   ---
  Safety only                                                                      12/31 (39)                                    ---
  Indeterminate                                                                    89/206 (43)                                   ---
  Study type                                                                           ---                    \<0.001[\*\*](#nt104){ref-type="table-fn"}
  Comparison: intervention with placebo                                           140/248 (56)                                   ---
   Randomization?                                                                      ---                                       0.75
    Yes                                                                           124/221 (56)                                   ---
    No                                                                             16/27 (59)                                    ---
  Comparison: intervention with other active agent                                 96/224 (43)                                   ---
   Randomization?                                                                      ---                                       0.17
    Yes                                                                            85/205 (41)                                   ---
    No                                                                             11/19 (58)                                    ---
  No comparison: intervention alone                                                47/138 (34)                                   ---
  Observational (no intervention)                                                  28/67 (42)                                    ---
  Study phase[a](#nt106){ref-type="table-fn"}                                          ---                                      0.008
  Phase I/phase II or phase II                                                     66/184 (36)                                   ---
  Phase II/phase III or phase III                                                 114/235 (49)                                   ---
  Phase IV                                                                         57/109 (52)                                   ---
  Trial size[b](#nt107){ref-type="table-fn"}                                           ---                                       0.37
  ≥160 Participants                                                               131/283 (46)                                   ---
  \<160 Participants                                                              120/282 (43)                                   ---
  Population studied                                                                   ---                                       ---
  Included older adults (≥65 y)                                                   230/499 (46)                   0.89[c](#nt108){ref-type="table-fn"}
  Included children (\<18 y)                                                       82/194 (42)                                0.22^\|d^
  Study location                                                                       ---                                       0.30
  US/Canada only                                                                  148/339 (44)                                   ---
  US/Canada and international                                                      20/43 (47)                                    ---
  International only                                                               87/192 (45)                                   ---
  Not provided                                                                     56/103 (54)                                   ---
  Trial end date                                                                       ---                    0.005[\*\*\*](#nt105){ref-type="table-fn"}
  No end date provided                                                            124/309 (40)                                   ---
  End date provided                                                               187/368 (51)                                   ---
   Before January 1, 2004                                                          75/123 (61)                                   ---
   Between January 1, 2004 and December 31, 2004 (inclusive)                       50/96 (52)                                    ---
   Between January 1, 2005 and December 31, 2005 (inclusive)                       62/149 (42)                                   ---

**\*:** *p*-Value for Pearson Chi-square testing the null hypothesis that publication rates among industry, government, and nonindustry/nongovernment sponsored trials are no different.

**\*\*:** *p*-Value for Pearson Chi-square testing the null hypothesis that publication rates among trials that compared an intervention with placebo, trials that compared an intervention with another active agent, trials with no comparison, and observational studies are no different.

**\*\*\*:** *p*-Value for Pearson Chi-square testing the null hypothesis that publication rates among trials with and without end dates provided are no different.

Among interventional trials that reported a trial phase only.

The median trial sample size was 160.

In comparison with trials that did not include older adults.

In comparison with trials that did not include children.

Among the 10% subsample of 677 trials, study end date was not reported for 309 (46%), although each had its registry updated within ClinicalTrials.gov to notify officials that the trial had been completed. Among 368 trials that provided an end date, 123 (33%) ended prior to 2004, 96 (26%) during 2004, and 149 (40%) during 2005. Trials primarily sponsored by industry, conducted only for safety, studied cancer, did not include children, and conducted in both US domestic and international sites were less likely to report an end date (*p*\<0.005). Trials that reported a study end date were more likely to be published when compared with trials that did not (51% versus 40%; relative risk \[RR\] = 1.27, 95% confidence interval \[CI\] 1.07--1.50; *p* = 0.005). Among trials that reported an end date, 75 of 123 (61%) completed prior to 2004, 50 of 96 (52%) completed during 2004, and 62 of 149 (42%) completed during 2005 were published (*p* = 0.006).

Among the 10% subsample, industry was the primary sponsor of 357 (53%) trials, government 122 (18%), and nongovernment/nonindustry 198 (29%). Trials primarily sponsored by industry were less likely to be published when compared with nongovernment/nonindustry sponsored trials (40% versus 56%; RR = 0.73, 95% CI 0.61--0.87; *p*\<0.001); there was no statistically significant difference in publication rates between industry and government primary sponsored trials (40% versus 47%; *p* = 0.22). Among government sponsored trials, only 42% of those primarily sponsored by the NIH were published (30 of 74). Among industry sponsors with ten or more trials in our subsample, publication rates varied widely: 13 of 14 (93%) trials primarily sponsored by Merck, seven of 11 (64%) by Amgen, and 15 of 24 (63%) by Johnson & Johnson were published, whereas only seven of 27 (26%) trials primarily sponsored by Novartis, nine of 34 (27%) by GlaxoSmithKline, and four of 14 (29%) by Sanofi-Aventis were published.

Among the 10% subsample, 248 (37%) trials compared an intervention with placebo (89% were randomized), 224 (33%) compared an intervention with another active agent (92% were randomized), 138 (20%) examined an intervention without a comparison group, and 67 (10%) were observational (no intervention). Trials comparing an intervention with placebo were more likely to be published when compared with other trial designs (56% versus 40%; RR = 1.42, 95% CI 1.21--1.66; *p*\<0.001), and phase II trials were less likely to be published when compared with phase III or phase IV trials (36% versus 50%; RR = 0.72, 95% CI 0.58--0.90; *p* = 0.002). Other examined trial characteristics were not significantly associated with publication: condition or population studied, study purpose or location, or trial size.

Among 311 published trials, 198 (64%) reported a primary outcome within ClinicalTrials.gov, nearly all of which (97%) matched the primary outcome measure in the published manuscript. However, the data quality varied markedly, particularly its degree of specificity with regards to providing the time period after which the outcome will be studied and how the outcome will be measured. As an example, one trial reported the primary outcome "change from baseline to 6-mo in distal femur bone mineral density," while another reported "bone mineral density."

Discussion {#s5}
==========

Our study demonstrates that the potential of ClinicalTrials.gov registry to address selective publication and better inform the public and professionals about the results from completed clinical trials is limited because critical information from trial registration, such as study contact, trial end date, and primary outcome, were not consistently reported. Moreover, publication rates among completed trials registered within ClinicalTrials.gov were low, even among trials with at least 4 y documented since study completion. Low publication rates were widespread among differing trial sponsors, conditions studied, study types, and locations. However, we also found significantly different publication rates among study types and primary sponsors, consistent with prior research [@pmed.1000144-Lexchin1]. Even when trials were found to be published, for the majority the citation was not available within ClinicalTrials.gov, which would have made it easy for the public and professionals to access results.

We expected that the trials we examined were likely to have been published in that they were recently completed after being registered at ClinicalTrials.gov within the past decade, ensuring that thet trial was in compliance with ICMJE requirements if the results were publishable. However, the recent nature of our sample is a possible explanation for our finding low rates of trial publication. Although we allowed at least 2 y after the study ended for publication, consistent with FDAAA legislation, rates were higher among those that ended longer ago. Nevertheless, publication rates reached only 60% among trials documented as having ended prior to 2004, an allowance of at least 4 y for trial publication. Importantly, all the trials included in our study had their registration updated to notify ClinicalTrials.gov that the trial had been completed.

Many studies have attempted to evaluate the extent of selective publication in the biomedical literature and found similarly low rates of publication [@pmed.1000144-Turner1],[@pmed.1000144-Chan1]--[@pmed.1000144-Dwan1], although none have used, to our knowledge, as large and as broadly representative a registry as ClinicalTrials.gov, particularly with regards to condition studied and study location, with the exception of two recent studies focused on the publication of trials submitted to the FDA [@pmed.1000144-Lee1],[@pmed.1000144-Rising1]. Other evidence concerning selective publication is anecdotal, such as the absence of 6 mo of trial data from a key publication describing the efficacy of celecoxib [@pmed.1000144-Silverstein1],[@pmed.1000144-Juni1], the delay of publication for two early trials of rofecoxib until after the medication was withdrawn from the market [@pmed.1000144-Mukherjee1]--[@pmed.1000144-Weaver1], and the aforementioned studies of rosiglitazone [@pmed.1000144-Nissen1], erythropoiesis-stimulating agents [@pmed.1000144-Bennett1], and antidepressants [@pmed.1000144-Turner1].

However, as described, low publications rates were not limited to specific trial sponsors, suggesting that selective publication is an issue among trials sponsored by both industry and government and reinforcing the importance of registries like ClinicalTrials.gov for addressing this problem. Selective publication may occur for several reasons, although our study was not designed to evaluate its causes. If trial results put either investigators or the study\'s sponsor at financial risk, they may be delayed or suppressed [@pmed.1000144-Blumenthal1]. In addition, if trial results contradict investigators\' beliefs, providing unexpected support (or lack of support) for a particular clinical practice, they may not be submitted for publication [@pmed.1000144-Blumenthal1]. This may be exacerbated by investigator reluctance to publish negative results given the need to highlight "positive, promising" findings for grant applications. Finally, researchers, reviewers, and editors have historically been more enthusiastic about positive or equivalence trials and less excited about negative trials [@pmed.1000144-DeAngelis1]; accordingly, these latter trials are submitted and accepted for publication less often [@pmed.1000144-Decullier1]--[@pmed.1000144-Dickersin2],[@pmed.1000144-Stern1],[@pmed.1000144-Dickersin3]. Suggestive of this, 70% of published manuscripts in our study from intervention-placebo or intervention-active trials were reported as positive, although we are unable to determine what proportion of the unpublished trials found positive results.

Although the FDAAA now requires reporting of trial results within 1 to 2 y after study completion within ClinicalTrials.gov, selective publication may not be fully remedied. The quality of the information provided for some data elements within ClinicalTrials.gov varied widely. It is not clear whether or how often the accuracy of the data is verified by the NLM, although those responsible for the conduct of the clinical trial are principally accountable for its quality and accuracy. Even though nearly all trials reported mandatory data elements, many entries were of poor quality and provided limited information, particularly the principal investigator/study contact. Reporting of optional data elements ranged widely and, similar to the mandatory data elements, many were of poor quality and provided limited information. As had been shown in prior research [@pmed.1000144-Zarin1], only 66% of trials reported their primary outcome measure, and outcomes were often vague and poorly specific among those that did, making it difficult or impossible to detect outcome reporting bias. Given the documented presence of outcome reporting bias among trials studied in other settings [@pmed.1000144-Turner1],[@pmed.1000144-Chan1],[@pmed.1000144-Chan2], the potential impact of ClinicalTrials.gov on outcome reporting bias deserves further research. Just as significant progress has been made with regards to improved reporting of the study intervention (i.e., drug name) within ClinicalTrials.gov [@pmed.1000144-Zarin2], progress can be made by mandating the registration of all information that is necessary for the public and profession to access and interpret trial results, including primary and secondary outcomes, study location, and enrollment, with clear field requirements to prevent vague reporting and improve data quality. Furthermore, we propose that either the NLM or another specified agency be given sufficient power of enforcement, including the capacity to assess fines or other penalties to sponsors or investigators who are not compliant with requirements.

One limitation of our study was that nearly half of the 10% subsample of trials among which we determined publication status did not report a trial end date, and those that did not were published at the lowest rates, preventing an assurance that all trials were allowed at least 2 y after study completion for trial publication. In addition, although all the trials included in our study had their registries updated to notify ClinicalTrials.gov that the trial had been completed, the date on which this specific notification was made was not available. This low rate of reporting of an optional data element ("study end date") in itself suggests that reporting of information needed to comprehensively assess trial progress and completion must be required and verified. In addition, we cannot be certain of the relationship between not reporting trial end date and publication. Not reporting an end date may indicate that study officials had determined that the trial would not be submitted for publication and thus made minimal efforts to fully update the trial\'s registration within ClinicalTrials.gov, such as by providing the actual trial end date, outside of providing notification that the trial had been completed. Similarly, the low response rate among investigators surveyed about completed yet unpublished registered trials may indicate that the trials were not published and investigators were instead focused on current study efforts. Nevertheless, rates of publication were low among both trials that did and did not report end dates.

There are other limitations to our study. Relevant publications may not have been identified in our review, partly because we limited our study to MEDLINE and did not search other databases, such as EMBASE or research conference proceedings (abstracts). However, EMBASE is not publicly accessible, requiring a subscription for access. Moreover, research abstracts are often preliminary and rarely provide all relevant efficacy and safety findings. Our search for publications was extensive, involving two independent investigators using a systematic method to query MEDLINE. If we were unable to identify a trial publication, it is unlikely that others using PubMed to find results from a trial from ClinicalTrials.gov would be able to consistently do so. In addition, some studies may have been made publicly available elsewhere. In response to criticism about selective publication, several pharmaceutical companies and their US trade association (Pharmaceutical Research and Manufacturers of America) have established registries to report results of their clinical trials [@pmed.1000144-GlaxoSmithKline1]--[@pmed.1000144-Pharmaceu1]. Although a useful step, these registries do not adequately address the issue of selective publication since the results are not subject to peer review and provide no assurance of complete reporting of efficacy and safety. Secondly, our sample size may have been too small for our analyses to have sufficient power to identify true differences in publication rates between trial subcategories, such as sponsorship or study purpose. Finally, many changes may have already been or will be made to ClinicalTrials.gov in response to addressing the new requirements enacted as part of the FDAAA. However, an important purpose of our study was to inform these efforts and future work will need to examine whether changes made the registry more effective.

The scientific community should be prioritizing the timely and accurate publication and dissemination of clinical trial results, regardless of the strength and direction of trial results. Current, up-to-date evidence is critical for clinicians, researchers, and patients, and late publication can impair and undermine evidence-based clinical practice almost as effectively as nonpublication. In addition, investigators have an obligation to ensure that the efforts of patients who volunteer as trial subjects are shared to advance science. Publication rates among completed trials registered within ClinicalTrials.gov were low, even among trials with at least 4 y since the study had ended. Critically, even among published trials, few reported the citation within ClinicalTrials.gov, a small but necessary step that should be required in order to make it easy for the public and the profession to have access to the trial results. The FDA needs a coordinated strategy for oversight and enforcement of the new requirements of the FDAAA, along with a commitment from industry, government, and all other trial sponsors, as well as the scientific community, to minimize selective publication of trials and ensure timely public and professional access to trial results.
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